Viemed Healthcare, Inc. (VMD) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VMD SEC filings page.
Viemed Healthcare, Inc. (VMD) reported $301.6M in revenue over the twelve months to Jun 30, 2026, up 25.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Viemed is scaling revenue with modest operating leverage, while heavy reinvestment keeps cash conversion below accounting profit.
Free-cash-flow margin rebounded from0.6% in FY2024 to4.4% in FY2025, but capital spending still consumed most operating cash flow. That means the accounting improvement translated into cash only after a large reinvestment charge, making cash generation more dependent on investment intensity than net income alone.
Gross margin narrowed to
Debt-to-equity reached 0.1x while liabilities rose to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Viemed Healthcare, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Viemed Healthcare, Inc. has an operating margin of 8.5%, meaning the company retains $8 of operating profit per $100 of revenue. This strong profitability earns a score of 68/100, reflecting efficient cost management and pricing power. This is up from 8.0% the prior year.
Viemed Healthcare, Inc.'s revenue surged 20.5% year-over-year to $270.3M, reflecting rapid business expansion. This strong growth earns a score of 83/100.
Viemed Healthcare, Inc. carries a low D/E ratio of 0.08, meaning only $0.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.
Viemed Healthcare, Inc.'s current ratio of 1.18 is below the typical benchmark, resulting in a score of 28/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Viemed Healthcare, Inc. has a free cash flow margin of 4.4%, earning a moderate score of 43/100. The company generates positive cash flow after capital investments, but with room for improvement.
Viemed Healthcare, Inc. earns a strong 10.9% return on equity (ROE), meaning it generates $11 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 79/100. This is up from 8.7% the prior year.
Viemed Healthcare, Inc. scores 6.51, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($371.4M) relative to total liabilities ($55.6M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Viemed Healthcare, Inc. passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Viemed Healthcare, Inc. generates $3.37 in operating cash flow ($51.9M OCF vs $15.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Viemed Healthcare, Inc. earns $19.42 in operating income for every $1 of interest expense ($22.9M vs $1.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Viemed Healthcare, Inc. generated $78.1M in revenue in Q2 2026. This represents an increase of 23.9% from the same quarter a year earlier. Against the prior quarter it is up 3.6%.
Viemed Healthcare, Inc.'s EBITDA was $4.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.0% from the same quarter a year earlier. Against the prior quarter it is down 59.3%.
Viemed Healthcare, Inc. reported $2.8M in net income in Q2 2026. This represents a decrease of 12.4% from the same quarter a year earlier. Against the prior quarter it is up 7.0%.
Viemed Healthcare, Inc. earned $0.07 per diluted share (EPS) in Q2 2026. This represents a decrease of 12.5% from the same quarter a year earlier. Against the prior quarter it is up 16.7%.
Cash & Balance Sheet
Viemed Healthcare, Inc. generated $7.4M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 80.4% from the same quarter a year earlier. Against the prior quarter it is up 447.6%.
Viemed Healthcare, Inc. held $10.7M in cash against $6.4M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Viemed Healthcare, Inc.'s gross margin was 57.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.
Viemed Healthcare, Inc.'s operating margin was 5.7% in Q2 2026, reflecting core business profitability. This is down 2.4 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.
Viemed Healthcare, Inc.'s net profit margin was 3.5% in Q2 2026, showing the share of revenue converted to profit. This is down 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.
Viemed Healthcare, Inc.'s ROE was 1.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.
Capital Allocation
Viemed Healthcare, Inc. invested $504K in research and development in Q2 2026. This represents a decrease of 40.5% from the same quarter a year earlier. Against the prior quarter it is down 13.0%.
Viemed Healthcare, Inc. spent $5.3M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 219.8% from the same quarter a year earlier. Against the prior quarter it is up 269.8%.
Viemed Healthcare, Inc. invested $8.5M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 4.1% from the same quarter a year earlier. Against the prior quarter it is up 26.0%.
VMD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $78.1M+23.9% | $75.4M+27.5% | $76.2M+25.5% | $71.9M+24.0% | $63.1M+14.7% | $59.1M+16.9% | $60.7M+19.6% | $58.0M+17.4% |
| Cost of Revenue | $33.0M+25.5% | $32.6M+26.1% | $32.1M+30.6% | $30.6M+29.3% | $26.3M+19.3% | $25.9M+24.3% | $24.6M+31.8% | $23.6M+25.4% |
| Gross Profit | $45.0M+22.6% | $42.8M+28.7% | $44.1M+22.0% | $41.3M+20.3% | $36.7M+11.7% | $33.3M+11.7% | $36.1M+12.5% | $34.4M+12.5% |
| R&D Expenses | $504K-40.5% | $579K-27.4% | $598K-25.5% | $775K+2.4% | $847K+11.7% | $797K+6.3% | $803K+23.3% | $757K+27.7% |
| SG&A Expenses | $37.1M+28.9% | $34.8M+22.4% | $32.2M+14.2% | $31.9M+19.7% | $28.8M+8.7% | $28.4M+14.6% | $28.2M+18.0% | $26.7M+12.8% |
| Operating Income | $4.5M-12.4% | $4.3M+11.8% | $8.4M+29.7% | $5.6M+0.2% | $5.1M+40.9% | $3.8M+74.3% | $6.5M+22.0% | $5.6M+33.8% |
| EBITDA | $4.8M-11.0% | $11.9M+14.0% | $29.6M+19.4% | $6.0M+1.1% | $5.4M+36.4% | $10.5M+23.1% | $24.8M+14.5% | $6.0M+29.2% |
| Interest Expense | $248K+87.9% | $305K+70.4% | $364K+147.6% | $507K+125.3% | $132K-48.0% | $179K+19.3% | $147K | $225K-5.1% |
| Income Tax | $1.2M-32.8% | $1.3M+34.2% | $2.2M+16.5% | $1.5M-3.7% | $1.7M+123.0% | $952K+83.8% | $1.9M+17.6% | $1.6M+20.8% |
| Net Income | $2.8M-12.4% | $2.6M-1.6% | $6.1M+37.2% | $3.5M-9.4% | $3.2M+115.1% | $2.6M+63.8% | $4.5M+29.6% | $3.9M+32.9% |
| EPS (Basic) | $0.07-12.5% | $0.070.0% | $0.14+27.3% | $0.09-10.0% | $0.08+100.0% | $0.07+75.0% | $0.11+22.2% | $0.10+25.0% |
| EPS (Diluted) | $0.07-12.5% | $0.060.0% | $0.14+27.3% | $0.09-10.0% | $0.08+100.0% | $0.06+50.0% | $0.11+37.5% | $0.10+42.9% |
| Diluted Shares (Avg) | 41M+0.1% | 40M-2.7% | N/A | 40M-0.7% | 41M+1.3% | 42M+2.6% | N/A | 41M+0.9% |
VMD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $204.2M+10.6% | $197.4M+10.8% | $199.2M+12.5% | $202.4M+19.4% | $184.6M+12.6% | $178.1M+15.0% | $177.1M+14.3% | $169.5M+13.5% |
| Current Assets | $54.0M-2.4% | $49.8M+1.4% | $48.5M-8.3% | $50.0M+4.8% | $55.3M+22.9% | $49.1M+27.2% | $52.9M+37.8% | $47.7M+33.0% |
| Cash & Equivalents | $10.7M-46.6% | $9.8M-3.9% | $13.5M-23.0% | $11.1M-2.0% | $20.0M+127.3% | $10.2M+39.0% | $17.5M+36.6% | $11.3M+12.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $5.3M+21.8% | $5.2M+14.9% | $5.0M+16.8% | $5.3M+22.2% | $4.3M-2.3% | $4.5M+3.7% | $4.3M-6.7% | $4.3M-7.7% |
| Accounts Receivable | $32.2M+21.4% | $31.2M+16.4% | $25.6M+2.7% | $27.4M+1.3% | $26.5M-1.9% | $26.8M+9.4% | $24.9M+35.0% | $27.1M+50.9% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $58.9M+78.7% | $58.9M+78.7% | $58.9M+78.7% | $58.5M+77.2% | $33.0M0.0% | $33.0M+10.8% | $33.0M+10.8% | $33.0M+11.1% |
| Total Liabilities | $58.3M+35.6% | $51.6M+24.8% | $55.6M+27.1% | $66.9M+56.5% | $43.0M+0.5% | $41.3M+7.1% | $43.8M+6.8% | $42.7M+5.3% |
| Current Liabilities | $47.9M+28.5% | $40.7M+14.7% | $41.1M+10.0% | $44.2M+21.3% | $37.3M+18.4% | $35.5M+17.8% | $37.3M+16.2% | $36.4M+15.5% |
| Non-Current Liabilities | $10.4M+81.6% | $10.9M+85.8% | $14.6M+126.3% | $22.7M+260.7% | $5.7M-49.4% | $5.8M-31.1% | $6.4M-27.4% | $6.3M-30.4% |
| Long-Term Debt | $6.4M+84.0% | $8.3M+136.1% | $11.3M+214.6% | $19.6M+436.6% | $3.5M-60.2% | $3.5M-40.2% | $3.6M-40.2% | $3.6M-54.9% |
| Total Equity | $144.0M+3.1% | $143.9M+6.8% | $141.5M+7.7% | $133.6M+6.9% | $139.7M+17.1% | $134.8M+15.9% | $131.4M+15.4% | $125.0M+14.8% |
| Retained Earnings | $108.2M+15.3% | $105.5M+16.2% | $102.9M+14.7% | $97.3M+13.9% | $93.8M+15.0% | $90.7M+13.2% | $89.7M+12.8% | $85.4M+12.3% |
VMD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $15.9M+29.8% | $8.1M+182.8% | $18.4M+23.0% | $18.4M+44.1% | $12.3M+20.3% | $2.9M+142.9% | $15.0M+12.8% | $12.7M-7.7% |
| Depreciation & Amortization | $388K+9.9% | $7.6M+15.2% | $7.6M+18.9% | $397K+14.1% | $353K-6.4% | $6.6M+5.2% | $6.4M+7.6% | $348K-16.9% |
| Stock-Based Compensation | $2.0M-13.2% | $2.5M+6.1% | N/A | $2.2M+27.3% | $2.3M+44.5% | $2.3M+61.4% | N/A | $1.7M+17.8% |
| Capital Expenditures | $8.5M+4.1% | $6.7M-56.6% | $8.7M-26.1% | $7.6M-30.6% | $8.1M-9.0% | $15.5M+157.8% | $11.8M+49.1% | $11.0M+48.6% |
| Free Cash Flow | $7.4M+80.4% | $1.4M+110.8% | $9.7M+207.3% | $10.7M+515.7% | $4.1M+230.5% | -$12.6M-161.4% | $3.2M-41.0% | $1.7M-72.8% |
| Investing Cash Flow | -$7.8M-353.9% | -$5.5M+35.7% | -$7.6M+17.2% | -$32.3M-550.0% | -$1.7M+84.5% | -$8.5M-59.0% | -$9.2M-22.8% | -$5.0M+41.6% |
| Financing Cash Flow | -$7.1M-965.0% | -$6.3M-271.2% | -$8.5M-2191.8% | $5.0M+196.2% | -$671K-127.0% | -$1.7M-27.2% | $404K+113.3% | -$5.2M+3.9% |
| Share Buybacks | $5.3M+219.8% | $1.4M | $0 | $11.6M | $1.7M | $0 | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
VMD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.7%-0.6pp | 56.8%+0.5pp | 57.9%-1.7pp | 57.5%-1.8pp | 58.3%-1.6pp | 56.3%-2.6pp | 59.5%-3.7pp | 59.3%-2.6pp |
| Operating Margin | 5.7%-2.4pp | 5.7%-0.8pp | 11.0%+0.4pp | 7.8%-1.9pp | 8.1%+1.5pp | 6.5%+2.1pp | 10.6%+0.2pp | 9.7%+1.2pp |
| Net Margin | 3.5%-1.5pp | 3.4%-1.0pp | 8.0%+0.7pp | 4.9%-1.8pp | 5.0%+2.3pp | 4.4%+1.3pp | 7.3%+0.6pp | 6.7%+0.8pp |
| Return on Equity | 1.9%-0.3pp | 1.8%-0.2pp | 4.3%+0.9pp | 2.6%-0.5pp | 2.3%+1.0pp | 1.9%+0.6pp | 3.4%+0.4pp | 3.1%+0.4pp |
| Return on Assets | 1.4%-0.4pp | 1.3%-0.2pp | 3.1%+0.6pp | 1.7%-0.6pp | 1.7%+0.8pp | 1.5%+0.4pp | 2.5%+0.3pp | 2.3%+0.3pp |
| Current Ratio | 1.13-0.4x | 1.22-0.2x | 1.18-0.2x | 1.13-0.2x | 1.48+0.1x | 1.38+0.1x | 1.42+0.2x | 1.31+0.2x |
| Debt-to-Equity | 0.040.0x | 0.060.0x | 0.08+0.1x | 0.15+0.1x | 0.020.0x | 0.030.0x | 0.030.0x | 0.030.0x |
| Asset Turnover | 0.380.0x | 0.38+0.1x | 0.380.0x | 0.360.0x | 0.340.0x | 0.330.0x | 0.340.0x | 0.340.0x |
| FCF Margin | 9.5%+3.0pp | 1.8%+23.2pp | 12.7%+7.5pp | 14.9%+11.9pp | 6.5%+4.3pp | -21.4%-11.8pp | 5.2%-5.3pp | 3.0%-10.0pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Viemed Healthcare, Inc. VMD | FY2025 | $270.3M | $15.4M | 5.7% | $371.4M | 65/100 |
| NANO-X IMAGING LTD NNOX | FY2025 | $13.0M | -$75.0M | N/A | $32.2M | 54/100 |
| Outset Medical, Inc. OM | FY2025 | $119.5M | -$81.7M | -68.3% | $79.3M | 61/100 |
| Brainsway Ltd. BWAY | FY2024 | $41.0M | $2.9M | 7.1% | $484.2M | 36/100 |
| Monogram Technologies Inc. MGRM | FY2024 | N/A | -$16.3M | N/A | $244.2M | — |
| Inogen Inc INGN | FY2025 | $348.7M | $22.7M | 6.5% | $177.5M | 42/100 |
Where Viemed Healthcare, Inc. Ranks
Frequently Asked Questions
What is Viemed Healthcare, Inc.'s annual revenue?
Viemed Healthcare, Inc. (VMD) reported $270.3M in total revenue for fiscal year 2025. This represents a 20.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Viemed Healthcare, Inc.'s revenue growing?
Viemed Healthcare, Inc. (VMD) revenue grew by 20.5% year-over-year, from $224.3M to $270.3M in fiscal year 2025.
Is Viemed Healthcare, Inc. profitable?
Yes, Viemed Healthcare, Inc. (VMD) reported a net income of $15.4M in fiscal year 2025, with a net profit margin of 5.7%.
What is Viemed Healthcare, Inc.'s EBITDA?
Viemed Healthcare, Inc. (VMD) had EBITDA of $51.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Viemed Healthcare, Inc. have?
As of fiscal year 2025, Viemed Healthcare, Inc. (VMD) had $13.5M in cash and equivalents against $11.3M in long-term debt.
What is Viemed Healthcare, Inc.'s gross margin?
Viemed Healthcare, Inc. (VMD) had a gross margin of 57.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Viemed Healthcare, Inc.'s operating margin?
Viemed Healthcare, Inc. (VMD) had an operating margin of 8.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Viemed Healthcare, Inc.'s net profit margin?
Viemed Healthcare, Inc. (VMD) had a net profit margin of 5.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Viemed Healthcare, Inc.'s return on equity (ROE)?
Viemed Healthcare, Inc. (VMD) has a return on equity of 10.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Viemed Healthcare, Inc.'s free cash flow?
Viemed Healthcare, Inc. (VMD) generated $11.9M in free cash flow during fiscal year 2025. This represents a 805.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Viemed Healthcare, Inc.'s operating cash flow?
Viemed Healthcare, Inc. (VMD) generated $51.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Viemed Healthcare, Inc.'s total assets?
Viemed Healthcare, Inc. (VMD) had $199.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Viemed Healthcare, Inc.'s capital expenditures?
Viemed Healthcare, Inc. (VMD) invested $40.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Viemed Healthcare, Inc. spend on research and development?
Viemed Healthcare, Inc. (VMD) invested $3.0M in research and development during fiscal year 2025.
What is Viemed Healthcare, Inc.'s current ratio?
Viemed Healthcare, Inc. (VMD) had a current ratio of 1.18 as of fiscal year 2025, which is considered adequate.
What is Viemed Healthcare, Inc.'s debt-to-equity ratio?
Viemed Healthcare, Inc. (VMD) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Viemed Healthcare, Inc.'s return on assets (ROA)?
Viemed Healthcare, Inc. (VMD) had a return on assets of 7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Viemed Healthcare, Inc.'s P/E ratio?
Viemed Healthcare, Inc. (VMD) trades at 24.8x earnings, its market capitalization divided by net income of $15.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $371.4M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Viemed Healthcare, Inc.'s price-to-sales ratio?
Viemed Healthcare, Inc. (VMD) trades at 1.2x sales, its market capitalization divided by revenue of $301.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $371.4M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Viemed Healthcare, Inc.'s Altman Z-Score?
Viemed Healthcare, Inc. (VMD) has an Altman Z-Score of 6.51, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Viemed Healthcare, Inc.'s Piotroski F-Score?
Viemed Healthcare, Inc. (VMD) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Viemed Healthcare, Inc.'s earnings high quality?
Viemed Healthcare, Inc. (VMD) has an earnings quality ratio of 3.37x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Viemed Healthcare, Inc. cover its interest payments?
Viemed Healthcare, Inc. (VMD) has an interest coverage ratio of 19.42x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Viemed Healthcare, Inc.?
Viemed Healthcare, Inc. (VMD) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.